N-Cyclopentylmethyl-tert.-Butylamin

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Cyclopentylmethyl-tert.-Butylamin
• 英文别名: N-(cyclopentylmethyl)-2-methylpropan-2-amine
• 化学式: C₁₀H₂₁N
• 分子量: 155.283
• InChiKey: LHRBLZJUKNECDF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-Cyclopentylmethyl-tert.-Butylamin 在 sodium hydride 、 二乙胺 作用下， 以 四氢呋喃 、 异丙醇 、 甲苯 为溶剂， 反应 1.0h， 生成 3-((1H-indol-4-yl)oxy)-N-(tert-butyl)-N-(cyclopentylmethyl)-2-methoxypropan-1-amine
  参考文献：
  名称：

  Structure–Activity Relationship and Biological Investigation of SR18292 (16), a Suppressor of Glucagon-Induced Glucose Production

  摘要：

  DOI：

  10.1021/acs.jmedchem.0c01450
• 作为产物：
  描述：

  环戊基甲醛 、 叔丁胺 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 18.0h， 生成 N-Cyclopentylmethyl-tert.-Butylamin
  参考文献：
  名称：

  Structure–Activity Relationship and Biological Investigation of SR18292 (16), a Suppressor of Glucagon-Induced Glucose Production

  摘要：

  DOI：

  10.1021/acs.jmedchem.0c01450

文献信息

• PYRROLOPYRAZINE INHIBITORS OF KINASES
  申请人：Penning Thomas D.

  公开号：US20110015172A1

  公开（公告）日：2011-01-20

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R 1a , R 1b , X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.

  本发明涉及式(I)的化合物或药用可接受的盐，其中R1a、R1b、X和Y在描述中有定义。本发明还涉及含有上述化合物的组合物，用于抑制Cdc7等激酶并治疗癌症等疾病的方法。
• NOVEL THIENOPYRROLE COMPOUNDS
  申请人：Wishart Neil

  公开号：US20110152243A1

  公开（公告）日：2011-06-23

  The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

  该发明提供了公式（I）的化合物，包括药用盐、前药、生物活性代谢物、立体异构体和同分异构体，其中变量在此处定义。该发明的化合物可用于治疗免疫和肿瘤疾病。
• PYRROLOPYRIDINE INHIBITORS OF KINASES
  申请人：Florjancic Alan S.

  公开号：US20110015173A1

  公开（公告）日：2011-01-20

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R 1a , R 1b , R 1c , X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.

  本发明涉及公式（I）的化合物或药用可接受的盐，其中R1a、R1b、R1c、X和Y在描述中有定义。本发明还涉及含有上述化合物的组合物，该组合物对抑制Cdc7等激酶以及治疗癌症等疾病有用。
• PEG-anchored rhodium polyether diphosphinite complex as an efficient homogeneous and recyclable catalyst for hydroaminomethylation of olefins
  作者：Shoeb R. Khan、Mayur V. Khedkar、Ziyauddin S. Qureshi、Dattatraya B. Bagal、Bhalchandra M. Bhanage

  DOI：10.1016/j.catcom.2011.08.033

  日期：2011.11

  A recyclable rhodium polyether diphosphinite complex anchored in polyethylene glycol [RhPEGD] was studied for hydroaminomethylation of various olefins with primary and secondary amines. The protocol was optimized with respect to various reaction parameters and the general applicability of catalyst for hydroaminomethylation of different functionalized olefins with corresponding amines was investigated

  研究了固定在聚乙二醇[RhPEGD]中的可循环利用的铑聚醚二亚膦酸酯络合物，用于各种烯烃与伯胺和仲胺的加氢氨基甲基化反应。该协议针对各种反应参数进行了优化，并研究了催化剂用于不同官能化烯烃与相应胺进行氢氨甲基化反应的一般适用性。在反应过程中，催化剂可溶于反应物/产物中，而在反应完成时可通过添加反溶剂以双相形式从反应介质中定量分离出来。该催化剂表现出显着的活性，随后被循环使用多达五个连续循环。
• 1,7-Naphthyridines as Pde4 Inhibitors
  申请人：Eldred Colin David

  公开号：US20080146563A1

  公开（公告）日：2008-06-19

  There are provided according to the invention novel compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof: wherein R 1 is selected from the group consisting of C 1-4 alkyl, C 4-6 cycloalkyl(CH 2 ) m —, methoxyC 2-4 alkyl, HOCH 2 CH 2 —, R 3 (O) 2 S(CH 2 ) 2 —, R 5 R 4 NCO(CH 2 ) n —, and heterocyclyl(CH 2 ) m — wherein any nitrogen heteroatom of the heterocyclyl radical may be unsubstituted or substituted by methyl; R 2 is hydrogen or methyl; R 3 is methyl or NH 2 ; R 4-5 independently represent methyl, m is 0, 1 or 2; and n is 1 or 2; or R 1 and R 2 together with the nitrogen atom to which they are attached may form a heterocyclyl ring, which may be unsubstituted or substituted by one or two substituents selected from the group consisting of; methyl, ═O and (CH 3 ) 2 N—.

  本发明提供了公式（I）的新化合物及其药学上可接受的盐和溶剂化物：其中R1选自由C1-4烷基，C4-6环烷基（CH2）m-，甲氧基C2-4烷基，HO -，R3（O）2S（ ）2-，R5R4NCO（ ）n-和杂环烷基（ ）m-，其中杂环烷基的任何氮杂原子可以未取代或被甲基取代；R2为氢或甲基；R3为甲基或NH2；R4-5独立地表示甲基，m为0，1或2；n为1或2；或R1和R2与它们所连接的氮原子一起可以形成一个杂环烷基环，该环可以未取代或被选自甲基，═O和（CH3）2N-的一或两个取代基所取代。